These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 30707602)

  • 21. Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.
    Salazar de Pablo G; Pastor Jordá C; Vaquerizo-Serrano J; Moreno C; Cabras A; Arango C; Hernández P; Veenstra-VanderWeele J; Simonoff E; Fusar-Poli P; Santosh P; Cortese S; Parellada M
    J Am Acad Child Adolesc Psychiatry; 2023 Feb; 62(2):151-168. PubMed ID: 35470032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. l -carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial.
    Nasiri M; Parmoon Z; Farahmand Y; Moradi A; Farahmand K; Moradi K; Basti FA; Mohammadi MR; Akhondzadeh S
    Int Clin Psychopharmacol; 2024 Jul; 39(4):232-239. PubMed ID: 37551601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole for the treatment of irritability and aggression in children and adolescents affected by autism spectrum disorders.
    Rizzo R; Pavone P
    Expert Rev Neurother; 2016 Aug; 16(8):867-74. PubMed ID: 27388494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety.
    Nikoo M; Radnia H; Farokhnia M; Mohammadi MR; Akhondzadeh S
    Clin Neuropharmacol; 2015; 38(1):11-7. PubMed ID: 25580916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.
    Hellings JA; Arnold LE; Han JC
    Expert Opin Pharmacother; 2017 Apr; 18(6):581-588. PubMed ID: 28335658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders.
    Ghanizadeh A; Moghimi-Sarani E
    BMC Psychiatry; 2013 Jul; 13():196. PubMed ID: 23886027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
    Ishitobi M; Kosaka H; Takahashi T; Yatuga C; Asano M; Tanaka Y; Ueno K; Okazaki R; Omori M; Hiratani M; Tomoda A; Wada Y
    Clin Neuropharmacol; 2013; 36(5):151-6. PubMed ID: 24045605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.
    Aman MG; Kasper W; Manos G; Mathew S; Marcus R; Owen R; Mankoski R
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):415-22. PubMed ID: 20973712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial severity and efficacy of risperidone in autism: Results from the RUPP trial.
    Levine SZ; Kodesh A; Goldberg Y; Reichenberg A; Furukawa TA; Kolevzon A; Leucht S
    Eur Psychiatry; 2016 Feb; 32():16-20. PubMed ID: 26802979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder.
    Dominick K; Wink LK; McDougle CJ; Erickson CA
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):397-401. PubMed ID: 26091194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment.
    Choi H; Kim JH; Yang HS; Kim JY; Cortese S; Smith L; Koyanagi A; Dragioti E; Radua J; Fusar-Poli P; Shin JI; Cheon KA; Solmi M
    Mol Autism; 2024 Jan; 15(1):7. PubMed ID: 38263251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance.
    Sugimoto Y; Yamamura K; Takayama T; Fukuta Y; Aoki K; Mikami K; Tomoda A
    BMC Psychiatry; 2021 Apr; 21(1):204. PubMed ID: 33888067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
    Aman M; Rettiganti M; Nagaraja HN; Hollway JA; McCracken J; McDougle CJ; Tierney E; Scahill L; Arnold LE; Hellings J; Posey DJ; Swiezy NB; Ghuman J; Grados M; Shah B; Vitiello B
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):482-93. PubMed ID: 26262903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.
    Marcus RN; Owen R; Kamen L; Manos G; McQuade RD; Carson WH; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1110-1119. PubMed ID: 19797985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychopharmacological interventions in autism spectrum disorder.
    Accordino RE; Kidd C; Politte LC; Henry CA; McDougle CJ
    Expert Opin Pharmacother; 2016; 17(7):937-52. PubMed ID: 26891879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
    Maher AR; Maglione M; Bagley S; Suttorp M; Hu JH; Ewing B; Wang Z; Timmer M; Sultzer D; Shekelle PG
    JAMA; 2011 Sep; 306(12):1359-69. PubMed ID: 21954480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
    Siafis S; Çıray O; Wu H; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; San José Cáceres A; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S
    Mol Autism; 2022 Mar; 13(1):10. PubMed ID: 35246237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised controlled trials of antipsychotics for people with autism spectrum disorder: a systematic review and a meta-analysis.
    Deb S; Roy M; Limbu B; Akrout Brizard B; Murugan M; Roy A; Santambrogio J
    Psychol Med; 2023 Dec; 53(16):7964-7972. PubMed ID: 37539448
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.